Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac risk.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  European Journal of Pharmacology

• Publication date

  2003-09-05

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0014-2999(03)02180-0PMID 14512100
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics.

  2001cited by this paper
• In Vitro Antibacterial Activities of AF 3013, the Active Metabolite of Prulifloxacin, against Nosocomial and Community Italian Isolates

  2001cited by this paper
• Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.

  2001cited by this paper
• Basic safety pharmacology: the cardiovascular system.

  2000cited by this paper
• Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions.

  2000cited by this paper
• Effects of fluoroquinolones on HERG currents.

  2000cited by this paper
• Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers

  1998cited by this paper
• Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration.

  1997cited by this paper
• Efficient Gene Transfer to Dispersed Human Pancreatic Islet Cells In Vitro Using Adenovirus-Polylysine/DNA Complexes or Polycationic Liposomes

  1996cited by this paper
• Pharmacokinetics and Safety of NM441, a New Quinolone, in Healthy Male Volunteers

  1994cited by this paper
• In vitro antibacterial activity of a new quinolone, NM394

  1991cited by this paper
• QTU‐Prolongation and Torsades de Pointes Induced by Putative Class III Antiarrhythmic Agents in the Rabbit: Etiology and Interventions

  1990cited by this paper
• Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches

  1981cited by this paper

• Metabolite-centric perspectives on QT prolongation: molecular mechanisms and clinical implications beyond the parent drug.

  2025cites this paper
• Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin

  2018cites this paper
• Nonclinical cardiovascular safety of pitolisant: comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro‐arrhythmia Assay initiative studies

  2017cites this paper
• Evidence for the hERG Liability of Antihistamines, Antipsychotics, and Anti‐Infective Agents: A Systematic Literature Review From the ARITMO Project

  2017cites this paper
• Ciprofloxacin , an antibiotic with cardiac actions on isolated rat hearts

  2017influential citation
• Toxicokinetics and Toxicodynamics of Anti-infective Agents

  2016cites this paper
• Safety Pharmacology II-CV, GI, Respiratory and Renal Safety

  2014cites this paper
• Effects of the fluoroquinolone antibacterial drug ciprofloxacin on ventricular repolarization in the halothane-anesthetized Guinea pig.

  2013cites this paper
• Combining structure- and ligand-based approaches for studies of interactions between different conformations of the hERG K+ channel pore and known ligands.

  2013cites this paper
• Cardiovascular and metabolic safety profiles of the fluoroquinolones

  2012cites this paper
• Prulifloxacin

  2012cites this paper
• Correlation among the toxicity profiling (28-days repeated oral dose toxicity), toxicokinetics and tissue distribution data of ulifloxacin, the active metabolite of prulifloxacin in Wistar albino rats.

  2012cites this paper
• Predicting the potency of hERG K+ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models

  2012cites this paper
• Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections.

  2011cites this paper
• 99mTc-prulifloxacin in artificially infected animals

  2011cites this paper
• Effects of Prulifloxacin on Cardiac Repolarization in Healthy Subjects

  2010cites this paper
• Prulifloxacin ECG Study

  2010cites this paper
• Accurate detection of drug-induced delayed ventricular repolarization with a suitable correction formula in Langendorff guinea pig heart.

  2010cites this paper
• Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties

  2009cites this paper
• Quantitative Structure–Activity Relationship Models for Predicting Biological Properties, Developed by Combining Structure‐ and Ligand‐Based Approaches: An Application to the Human Ether‐a‐go‐go‐Related Gene Potassium Channel Inhibition

  2009cites this paper
• Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period.

  2009cites this paper
• Prulifloxacin: clinical studies of a broad-spectrum quinolone agent.

  2009cites this paper
• A Composite Model for hERG Blockade

  2008cites this paper
• Four-membered Rings with One Sulfur and One Nitrogen Atom

  2008cites this paper
• Safety assessment of biopharmaceuticals: Japanese perspective on ICH S6 guideline maintenance.

  2008cites this paper
• Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis

  2007cites this paper
• Safety Pharmacology II-CV, GI, Respiratory and Renal Safety

  2007cites this paper
• Miscellaneous antibacterial drugs

  2007cites this paper
• Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs.

  2007cites this paper
• Pharmacologic characteristics of prulifloxacin.

  2006cites this paper
• Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias.

  2006cites this paper
• Insights for human ether-a-go-go-related gene potassium channel inhibition using recursive partitioning and Kohonen and Sammon mapping techniques.

  2006cites this paper
• Prulifloxacin: a new antibacterial fluoroquinolone

  2006cites this paper
• Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin

  2006influential citation
• No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic‐AV block

  2006cites this paper
• Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects.

  2006cites this paper
• QT PRODACT: a multi-site study of in vitro action potential assays on 21 compounds in isolated guinea-pig papillary muscles.

  2005cites this paper
• Comparative assessment of prurifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia.

  2004cites this paper
• The Journal of Toxicological Sciences

  2003cites this paper